Phase 1 Study of Safety, Tolerability and Pharmacokinetics of SPR994
A Two-part, Double-blind, Placebo-controlled, Phase I Study of the Safety, Tolerability and Pharmacokinetics of SPR994 Following Single and Multiple Ascending Doses of SPR994 Administered Orally in Healthy Volunteers
Sponsor: CPR Pharma Services Pty Ltd, Australia
Listed as NCT03395249, this PHASE1 trial focuses on Healthy Volunteers and remains completed. Sponsored by CPR Pharma Services Pty Ltd, Australia, it has been updated 8 times since 2017, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
8 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE1
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE1
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE1
-
Sep 2018 — Jan 2021 [monthly]
Completed PHASE1
Status: Recruiting → Completed
-
Jun 2018 — Sep 2018 [monthly]
Recruiting PHASE1
▶ Show 3 earlier versions
-
Apr 2018 — Jun 2018 [monthly]
Recruiting PHASE1
-
Feb 2018 — Apr 2018 [monthly]
Recruiting PHASE1
-
Jan 2018 — Feb 2018 [monthly]
Recruiting PHASE1
First recorded
Oct 2017
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- CPR Pharma Services Pty Ltd, Australia
- Spero Therapeutics
For direct contact, visit the study record on ClinicalTrials.gov .